KLRG1 expression identifies short-lived Foxp3⁺ T_reg effector cells with functional plasticity in islets of NOD mice

References

• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003;4:330–336.
   PubMed Web of Science ®Google Scholar
• Chen Z, Herman AE, Matos M, et al. Where CD4 + CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med. 2005;202:1387–1397.
   PubMed Web of Science ®Google Scholar
• Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 1997;7:727–738.
   PubMed Web of Science ®Google Scholar
• Anderson MS, Bluestone JA. THE NOD MOUSE: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447–485.
   PubMed Web of Science ®Google Scholar
• Tritt M, Sgouroudis E, d’Hennezel E, et al. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes. 2008;57:113–123.
   PubMed Web of Science ®Google Scholar
• Sgouroudis E, Albanese A, Piccirillo CA. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J Immunol. 2008;181:6283–6292.
   PubMed Web of Science ®Google Scholar
• Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–440.
   PubMed Web of Science ®Google Scholar
• Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–697.
   PubMed Web of Science ®Google Scholar
• Kornete M, Sgouroudis E, Piccirillo CA. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice. J Immunol. 2012;188:1064–1074.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711–2720.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–499.
   PubMed Web of Science ®Google Scholar
• Tessmer MS, Fugere C, Stevenaert F, et al. KLRG1 binds cadherins and preferentially associates with SHIP-1. Int Immunol. 2007;19:391–400.
   PubMed Web of Science ®Google Scholar
• Grundemann C, Bauer M, Schweier O, et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol. 2006;176:1311–1315.
   PubMed Web of Science ®Google Scholar
• Ito M, Maruyama T, Saito N, et al. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med. 2006;203:289–295.
   PubMed Web of Science ®Google Scholar
• Robbins SH, Nguyen KB, Takahashi N, et al. Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J Immunol. 2002;168:2585–2589.
   PubMed Web of Science ®Google Scholar
• Van den Bossche J, Malissen B, Mantovani A, et al. Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood. 2012;119:1623–1633.
   PubMed Web of Science ®Google Scholar
• van Leeuwen EMM, de Bree GJ, ten Berge IJM, et al. Human virus-specific CD8+ T cells: diversity specialists. Immunol Rev. 2006;211:225–235.
   PubMed Web of Science ®Google Scholar
• Cheng G, Yuan X, Tsai MS, et al. IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells. J Immunol. 2012;189:1780–1791.
   PubMed Web of Science ®Google Scholar
• Tauro S, Nguyen P, Li B, et al. Diversification and senescence of Foxp3+ regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol. 2013;43:1195–1207.
   PubMed Web of Science ®Google Scholar
• Liston A, Piccirillo CA. Developmental plasticity of murine and human Foxp3(+) regulatory T cells. Adv Immunol. 2013;119:85–106.
   PubMed Web of Science ®Google Scholar
• Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000–1007.
   PubMed Web of Science ®Google Scholar
• McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011;186:3918–3926.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Mariotti-Ferrandiz ME, Wang Y, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA. 2009;106:1903–1908.
   PubMed Web of Science ®Google Scholar
• Yurchenko K, Shio M, Huang TC, et al. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One. 2012;7:e35572.
   PubMed Web of Science ®Google Scholar
• Herman AE, Freeman GJ, Mathis D, et al. CD4 + CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004;199:1479–1489.
   PubMed Web of Science ®Google Scholar
• Feuerer M, Hill JA, Kretschmer K, et al. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci USA. 2010;107:5919–5924.
   PubMed Web of Science ®Google Scholar
• Beyersdorf N, Ding X, Tietze JK, et al. Characterization of mouse CD4 T cell subsets defined by expression of KLRG1. Eur J Immunol. 2007;37:3445–3454.
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153–165.
   PubMed Web of Science ®Google Scholar
• Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29:44–56.
   PubMed Web of Science ®Google Scholar
• Long SA, Buckner JH, Greenbaum CJ. IL-2 therapy in type 1 diabetes: “trials” and tribulations. Clin Immunol. 2013;149:324–331.
   PubMed Web of Science ®Google Scholar